Journal: Oncology Letters

Article Title: Prognostic significance of the expression of HER family members in primary osteosarcoma

doi: 10.3892/ol.2018.8931

Figure Lengend Snippet: Immunohistochemical expression of HER family members in osteosarcoma specimens. (A) High EGFR expression: Predominantly membranous with some cytoplasmic brown staining (arrow). (B) Low EGFR expression. (C) High HER-2 expression: Predominantly cytoplasmic brown staining (arrow). (D) Low HER-2 expression. (E) High HER-3 expression: Predominantly nuclear and cytoplasmic brown staining (arrow). (F) Low HER-3 expression. (G) High HER-4 expression: Predominantly nuclear and cytoplasmic brown staining (arrow). (H) Low HER-4 expression. (I) Final HER expression score demonstrating no significant difference among the expression levels of the HER family members. The box-plot was obtained using GraphPad Prism 5.0 (GraphPad Software Inc., San Diego, CA, USA) (original magnification of Fig. A-H, ×200). HER, human epidermal growth factor receptor.

Article Snippet: The sections were then immunostained with anti-EGFR (rabbit monoclonal EP38Y; cat no. ab52894; 1:50 dilution), anti-HER-2 (mousemonoclonalHRB2/451; cat no. ab187288; 1:100 dilution), anti-HER-3 (mouse monoclonalRTJ2; cat no. ab20161; 1:50 dilution) or anti-HER-4 (mouse monoclonal5G6B4; cat. no. ab204959; 1:50 dilution) (all Abcam, Cambridge, MA, USA) and incubated overnight at 4°C.

Techniques: Immunohistochemical staining, Expressing, Staining, Software

Journal: Oncology Letters

Article Title: Prognostic significance of the expression of HER family members in primary osteosarcoma

doi: 10.3892/ol.2018.8931

Figure Lengend Snippet: Kaplan-Meier analyses of PFS and OS time in stage I–IIB osteosarcoma patients. Significant differences in (A) PFS (P=0.033) and (B) OS (P=0.041) time were found between the high and low EGFR expression groups. Significant differences in (C) PFS (P=0.001) and (D) OS (P=0.006) time were found between the high and low HER-3 expression groups. Significant differences in (E) PFS (P=0.010) and (F) OS (P=0.015) time were found between the high and low HER-4 expression groups. HER, human epidermal growth factor receptor; PFS, progression-free survival; OS, overall survival.

Article Snippet: The sections were then immunostained with anti-EGFR (rabbit monoclonal EP38Y; cat no. ab52894; 1:50 dilution), anti-HER-2 (mousemonoclonalHRB2/451; cat no. ab187288; 1:100 dilution), anti-HER-3 (mouse monoclonalRTJ2; cat no. ab20161; 1:50 dilution) or anti-HER-4 (mouse monoclonal5G6B4; cat. no. ab204959; 1:50 dilution) (all Abcam, Cambridge, MA, USA) and incubated overnight at 4°C.

Techniques: Expressing

Journal: Oncology Letters

Article Title: Prognostic significance of the expression of HER family members in primary osteosarcoma

doi: 10.3892/ol.2018.8931

Figure Lengend Snippet: Kaplan-Meier analyses of PFS and OS time in stage IIB osteosarcoma patients. Significant differences of PFS time were found between the high and low (A) HER-4 (P=0.002) expression groups and (B) EGFR/HER-4 (P<0.001) expression groups. Significant differences of OS time were found between the high and low (C) HER-4 (P=0.011) expression groups and (D) EGFR/HER-4 (P<0.001) expression groups. HER, human epidermal growth factor receptor; PFS, progression-free survival; OS, overall survival.

Article Snippet: The sections were then immunostained with anti-EGFR (rabbit monoclonal EP38Y; cat no. ab52894; 1:50 dilution), anti-HER-2 (mousemonoclonalHRB2/451; cat no. ab187288; 1:100 dilution), anti-HER-3 (mouse monoclonalRTJ2; cat no. ab20161; 1:50 dilution) or anti-HER-4 (mouse monoclonal5G6B4; cat. no. ab204959; 1:50 dilution) (all Abcam, Cambridge, MA, USA) and incubated overnight at 4°C.

Techniques: Expressing